πŸ‡ΊπŸ‡Έ FDA
Patent

US 9834787

Targeted integration into stem cells

granted A61PA61P7/04

Quick answer

US patent 9834787 (Targeted integration into stem cells) held by Sangamo Therapeutics, Inc. expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P7/04